Pulmonary eosinophilia is attenuated by early responding CD8+ memory T cells in a murine model of RSV vaccine-enhanced disease

Whitney W. Stevens, Jie Sun, Jonathan P. Castillo, Thomas J. Braciale

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Vaccination with formalin-inactivated respiratory syncytial virus (RSV) vaccine results in enhanced respiratory tract inflammation and injury following subsequent RSV infection. RSV vaccine-enhanced disease can also be produced in mice by prior vaccination with a vaccinia virus vector containing the RSV G protein, followed by intranasal infectious RSV challenge, a process characterized by induction of a potent memory CD4+ T-cell response to challenge infection with some features characteristic of Th-2 CD4+ T-cell responses, including increased eosinophil accumulation in pulmonary inflammatory infiltrates. The adaptive immune response to the RSV G protein in immunized BALB/c mice is characterized by a weak or absent primary and secondary recall CD8+ T-cell response. These and related results have led to the hypothesis that the failure of the infected animals to mount an effective CD8+ memory T-cell (CD8+ Tm) response in this model could account for the pulmonary eosinophilia associated with the development of enhanced disease, and that CD8+ T cells may control the development of eosinophilia. In this study, we investigated how and when the generation of a CD8+ Tm response to RSV infection might affect the development of pulmonary eosinophilia in this model of vaccine-enhanced disease. By defining the CD8+ T-cell response kinetics and monitoring lung parenchymal eosinophil accumulation, we show that the establishment of an RSV-specific CD8+ Tm response in the infected lungs early after challenge infection (i.e., within the first 3 d of RSV infection) is necessary and sufficient to control pulmonary eosinophilia development. Additionally, our work suggests that the mechanism by which CD8+ T cells regulate this process is not by modulating the differentiation or development of the CD4 + Tm response. Rather, we demonstrate that IL-10 produced by early responding CD8+ Tm cells may regulate the pulmonary eosinophilia development observed in RSV vaccine-enhanced disease.

Original languageEnglish (US)
Pages (from-to)243-251
Number of pages9
JournalViral Immunology
Volume22
Issue number4
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Respiratory Syncytial Virus Vaccines
Pulmonary Eosinophilia
Respiratory Syncytial Viruses
T-Lymphocytes
Respiratory Syncytial Virus Infections
GTP-Binding Proteins
Eosinophils
Lung
Vaccination
Inactivated Vaccines
Vaccinia virus
Eosinophilia
Adaptive Immunity
Infection
Respiratory System
Interleukin-10
Formaldehyde
Vaccines
Inflammation
Wounds and Injuries

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Molecular Medicine

Cite this

Pulmonary eosinophilia is attenuated by early responding CD8+ memory T cells in a murine model of RSV vaccine-enhanced disease. / Stevens, Whitney W.; Sun, Jie; Castillo, Jonathan P.; Braciale, Thomas J.

In: Viral Immunology, Vol. 22, No. 4, 01.07.2009, p. 243-251.

Research output: Contribution to journalArticle

Stevens, Whitney W. ; Sun, Jie ; Castillo, Jonathan P. ; Braciale, Thomas J. / Pulmonary eosinophilia is attenuated by early responding CD8+ memory T cells in a murine model of RSV vaccine-enhanced disease. In: Viral Immunology. 2009 ; Vol. 22, No. 4. pp. 243-251.
@article{b5b6b89851304538bafdb91c876866de,
title = "Pulmonary eosinophilia is attenuated by early responding CD8+ memory T cells in a murine model of RSV vaccine-enhanced disease",
abstract = "Vaccination with formalin-inactivated respiratory syncytial virus (RSV) vaccine results in enhanced respiratory tract inflammation and injury following subsequent RSV infection. RSV vaccine-enhanced disease can also be produced in mice by prior vaccination with a vaccinia virus vector containing the RSV G protein, followed by intranasal infectious RSV challenge, a process characterized by induction of a potent memory CD4+ T-cell response to challenge infection with some features characteristic of Th-2 CD4+ T-cell responses, including increased eosinophil accumulation in pulmonary inflammatory infiltrates. The adaptive immune response to the RSV G protein in immunized BALB/c mice is characterized by a weak or absent primary and secondary recall CD8+ T-cell response. These and related results have led to the hypothesis that the failure of the infected animals to mount an effective CD8+ memory T-cell (CD8+ Tm) response in this model could account for the pulmonary eosinophilia associated with the development of enhanced disease, and that CD8+ T cells may control the development of eosinophilia. In this study, we investigated how and when the generation of a CD8+ Tm response to RSV infection might affect the development of pulmonary eosinophilia in this model of vaccine-enhanced disease. By defining the CD8+ T-cell response kinetics and monitoring lung parenchymal eosinophil accumulation, we show that the establishment of an RSV-specific CD8+ Tm response in the infected lungs early after challenge infection (i.e., within the first 3 d of RSV infection) is necessary and sufficient to control pulmonary eosinophilia development. Additionally, our work suggests that the mechanism by which CD8+ T cells regulate this process is not by modulating the differentiation or development of the CD4 + Tm response. Rather, we demonstrate that IL-10 produced by early responding CD8+ Tm cells may regulate the pulmonary eosinophilia development observed in RSV vaccine-enhanced disease.",
author = "Stevens, {Whitney W.} and Jie Sun and Castillo, {Jonathan P.} and Braciale, {Thomas J.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1089/vim.2009.0016",
language = "English (US)",
volume = "22",
pages = "243--251",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Pulmonary eosinophilia is attenuated by early responding CD8+ memory T cells in a murine model of RSV vaccine-enhanced disease

AU - Stevens, Whitney W.

AU - Sun, Jie

AU - Castillo, Jonathan P.

AU - Braciale, Thomas J.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Vaccination with formalin-inactivated respiratory syncytial virus (RSV) vaccine results in enhanced respiratory tract inflammation and injury following subsequent RSV infection. RSV vaccine-enhanced disease can also be produced in mice by prior vaccination with a vaccinia virus vector containing the RSV G protein, followed by intranasal infectious RSV challenge, a process characterized by induction of a potent memory CD4+ T-cell response to challenge infection with some features characteristic of Th-2 CD4+ T-cell responses, including increased eosinophil accumulation in pulmonary inflammatory infiltrates. The adaptive immune response to the RSV G protein in immunized BALB/c mice is characterized by a weak or absent primary and secondary recall CD8+ T-cell response. These and related results have led to the hypothesis that the failure of the infected animals to mount an effective CD8+ memory T-cell (CD8+ Tm) response in this model could account for the pulmonary eosinophilia associated with the development of enhanced disease, and that CD8+ T cells may control the development of eosinophilia. In this study, we investigated how and when the generation of a CD8+ Tm response to RSV infection might affect the development of pulmonary eosinophilia in this model of vaccine-enhanced disease. By defining the CD8+ T-cell response kinetics and monitoring lung parenchymal eosinophil accumulation, we show that the establishment of an RSV-specific CD8+ Tm response in the infected lungs early after challenge infection (i.e., within the first 3 d of RSV infection) is necessary and sufficient to control pulmonary eosinophilia development. Additionally, our work suggests that the mechanism by which CD8+ T cells regulate this process is not by modulating the differentiation or development of the CD4 + Tm response. Rather, we demonstrate that IL-10 produced by early responding CD8+ Tm cells may regulate the pulmonary eosinophilia development observed in RSV vaccine-enhanced disease.

AB - Vaccination with formalin-inactivated respiratory syncytial virus (RSV) vaccine results in enhanced respiratory tract inflammation and injury following subsequent RSV infection. RSV vaccine-enhanced disease can also be produced in mice by prior vaccination with a vaccinia virus vector containing the RSV G protein, followed by intranasal infectious RSV challenge, a process characterized by induction of a potent memory CD4+ T-cell response to challenge infection with some features characteristic of Th-2 CD4+ T-cell responses, including increased eosinophil accumulation in pulmonary inflammatory infiltrates. The adaptive immune response to the RSV G protein in immunized BALB/c mice is characterized by a weak or absent primary and secondary recall CD8+ T-cell response. These and related results have led to the hypothesis that the failure of the infected animals to mount an effective CD8+ memory T-cell (CD8+ Tm) response in this model could account for the pulmonary eosinophilia associated with the development of enhanced disease, and that CD8+ T cells may control the development of eosinophilia. In this study, we investigated how and when the generation of a CD8+ Tm response to RSV infection might affect the development of pulmonary eosinophilia in this model of vaccine-enhanced disease. By defining the CD8+ T-cell response kinetics and monitoring lung parenchymal eosinophil accumulation, we show that the establishment of an RSV-specific CD8+ Tm response in the infected lungs early after challenge infection (i.e., within the first 3 d of RSV infection) is necessary and sufficient to control pulmonary eosinophilia development. Additionally, our work suggests that the mechanism by which CD8+ T cells regulate this process is not by modulating the differentiation or development of the CD4 + Tm response. Rather, we demonstrate that IL-10 produced by early responding CD8+ Tm cells may regulate the pulmonary eosinophilia development observed in RSV vaccine-enhanced disease.

UR - http://www.scopus.com/inward/record.url?scp=67849134920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67849134920&partnerID=8YFLogxK

U2 - 10.1089/vim.2009.0016

DO - 10.1089/vim.2009.0016

M3 - Article

C2 - 19594395

AN - SCOPUS:67849134920

VL - 22

SP - 243

EP - 251

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 4

ER -